对NRF2/β-TrCP轴的特定向促进了NASH的有益影响
Raquel Fernández-Ginés1, José Antonio Encinar2, Maribel Escoll1
1Instituto de Investigaciones Biomédicas "Alberto Sols" CSIC-UAM, Instituto de Investigación Sanitaria La Paz (IdiPaz) and Department of Biochemistry, Faculty of Medicine, Autonomous University of Madrid, Madrid, Spain; Centro de Investigación Biomédica en Red Sobre Enfermedades Neurodegenerativas (CIBERNED), ISCIII, Madrid, Spain.
一种新型的蛋白质-蛋白质相互作用抑制剂PHAR在治疗非酒精性脂肪肝炎 (NASH) 中表现有前途. 它轻微激活NRF2,在小鼠模型中保护肝脏脂肪积累和纤维化进展.
科学领域:
- 肝病学和胃肠病学 肝病学和胃肠学
- 分子生物学分子生物学
- 药物发现 药物发现 药物发现
背景情况:
- 非酒精性脂肪肝炎 (NASH) 是一种普遍存在的慢性肝病,缺乏经批准的治疗方法.
- 转录因子NRF2是NASH的潜在治疗点.
- 现有的NRF2激活剂具有局限性,需要使用替代策略.
研究的目的:
- 评估PHAR,NRF2/β-TrCP的蛋白-蛋白相互作用抑制剂,在预防NASH及其进展为纤维化的疗效.
- 评估PHAR在肝细胞中选择性激活NRF2的能力.
主要方法:
- 证实了PHAR在肝细胞,库弗弗细胞和星状细胞中的NRF2激活.
- 我们使用了STAM小鼠模型,模仿NASH和胰岛素抵抗.
- 使用磁共振成像 (MRI) 和转录组分析来评估NASH标志物和基因表达.
主要成果:
- 在STAM小鼠模型中,PHAR证明了对肝脏脂肪积累的保护作用.
- PHAR减弱了NASH进展的关键标志物:肥胖症,肝细胞膨胀,炎症和纤维化.
- 转录组分析揭示了PHAR对抗纤维化,亲纤维化,细胞外矩阵重塑和炎症基因的调节.
结论:
- 在相关的肝细胞类型中,PHAR有效地激活NRF2.
- 在临床前模型中,PHAR减轻了NASH的发展和进展到肝纤维化.
- 通过通过PHAR轻度激活NRF2的向,为NASH提供了一个有前途的治疗策略.
更多相关视频
08:16Method for the Assessment of Effects of a Range of Wavelengths and Intensities of Red/near-infrared Light Therapy on Oxidative Stress In Vitro
Published on: March 21, 2015
09:53Herbal Munziq Ameliorates Myocardial Ischemia-Reperfusion Injury by Inhibiting Inflammation
Published on: January 10, 2025
相关概念视频
Transducer Mechanism: Nuclear Receptors
About 48 different soluble family members of nuclear receptors are identified that can be divided into two main classes:
Targeted Cancer Therapies
There are several types of targeted therapies against...
Electron Transport Chain: Complex I and II
ROS generation is regulated and maintained at moderate levels necessary...
NF-κB-dependent Signaling Pathway
NF-κB-dependent Signaling Mechanism
The...
